Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091595 | 0.81 | PARP10 (0.41) | MAPTKDM4EGAAHSD17B10FYN | |
| SCHEMBL20548510 | 0.80 | ATAD2 (0.55) | ATAD2NR1H2NR1H3MAPTKMT2A | |
| SCHEMBL29713184 | 0.80 | ATAD2 (0.55) | ATAD2NR1H2NR1H3MAPTKMT2A | |
| SCHEMBL6705947 | 0.79 | CASP3 (0.49) | MAPTADRA2AADRA2BADRA2CBRPF1 | |
| SCHEMBL31444689 | 0.79 | BRD4 (0.45) | MAPTKMT2AMEN1ADRA2AADRA2B | |
| SCHEMBL23535782 | 0.77 | LMNA (0.49) | NR1H2NR1H3MAPTKDM4EL3MBTL1 | |
| SCHEMBL30040376 | 0.77 | LMNA (0.49) | NR1H2NR1H3MAPTKDM4EL3MBTL1 | |
| SCHEMBL5903145 | 0.76 | ATAD2 (0.51) | ATAD2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL520157 | 0.75 | TRIM24 (0.49) | ATAD2KMT2AMEN1GAAACVR1 | |
| SCHEMBL904835 | 0.74 | BRPF1 (0.50) | NR1H2NR1H3KMT2AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10016439-B2 | Fused imidazole compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | ATAD2 2862/4885NR1H2 653/4885NR1H3 897/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | ATAD2 2862/4885NR1H2 653/4885NR1H3 897/4885 |
| US-10016439-B2 | Fused imidazole compounds | GABRA5, CHRNA5, GABRP | ATAD2 2862/4885NR1H2 653/4885NR1H3 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.